certain disorders that begin during development, such as progeroid syndromes (accelerated aging-like states), and that are associated with high senescent cell burden can be alleviated by senolytics in mouse models. 2,3 If further preclinical work supports this, situations could be envisaged in which clinical trials with senolytics in children are warranted.We agree about protective roles of senescent cells in cancer and would not advocate interfering with the pathways through which senescent cells develop, including p16 Ink4A or p53. Advantages of our hit-and-run senolytic approach are that it does not interfere with senescence-inducing but cancerprotective pathways. Among other inducers, oncoproteins and potentially oncogenic mutations can cause cells to become senescent, 3 and senolytics eliminate already senescent cells, theoretically removing these potentially precancerous senescent cells. In mice, senolytics delay all causes of death, including cancers. 4 The first senolytics were discovered in part based on the hypothesis that drugs that cause cancer cell death through apoptosis could be senolytic. 2 As O'Sullivan and colleagues indicate, an advantage of our hit-and-run approach is that senolytic administration can be delayed in situations in which there could be complications, such as during wound healing. However, early and mostly unpublished data are beginning to suggest that senolytic administration during certain time windows with respect to wounding (eg, shortly before surgery) could actually enhance wound healing. More work is needed to test this speculation.We agree that cell senescence-related fibrosis can potentially be beneficial during situations such as wound healing. Conversely, senescence-related fibrosis can also be detrimental; for example, in the pathogenesis of liver cirrhosis or idiopathic pulmonary fibrosis. Both of these fibrosis-related conditions are alleviated by senolytics in preclinical models. 3 Clinical trials of senolytics are underway for idiopathic pulmonary fibrosis.We emphasize that senolytics should not be used in clinical practice or by the general population unless and until clinical trials demonstrate safety and effectiveness. These clinical trials will likely uncover adverse effects of senolytics as a class. Furthermore, there are agent-specific adverse effects of particular senolytics. For example, navitoclax (ABT-263), 5 a Bcl-2 pathway inhibitor, can cause serious thrombocytopenia, even with limited dosing, 6 constraining its translational potential. The individual senolytics discovered so far target different subpopulations of senescent cells and so can be anticipated to differ in effectiveness for particular indications. This suggests that an individualized approach will be optimal for selecting senolytic regimens for particular patients, if and when senolytics are shown to be safe and effective in clinical trials.